MetLife Investment Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-30,585
| Closed | -$1.18M | – | 3021 |
|
|
2023
Q2 | $1.18M | Buy |
30,585
+4,090
| +15% | +$105K | 0.01% | 1174 |
|
|
2023
Q1 | $613K | Hold |
26,495
| – | – | ﹤0.01% | 1507 |
|
|
2022
Q4 | $694K | Hold |
26,495
| – | – | 0.01% | 1430 |
|
|
2022
Q3 | $521K | Buy |
26,495
+4,391
| +20% | +$88.1K | ﹤0.01% | 1603 |
|
|
2022
Q2 | $387K | Buy |
22,104
+2,265
| +11% | +$35.6K | ﹤0.01% | 1842 |
|
|
2022
Q1 | $325K | Buy |
19,839
+7,322
| +58% | +$99.6K | ﹤0.01% | 2052 |
|
|
2021
Q4 | $204K | Hold |
12,517
| – | – | ﹤0.01% | 2040 |
|
|
2021
Q3 | $160K | Hold |
12,517
| – | – | ﹤0.01% | 2221 |
|
|
2021
Q2 | $177K | Buy |
+12,517
| New | +$200K | ﹤0.01% | 2239 |
|
|
2021
Q1 | – | Sell |
-6,444
| Closed | -$102K | – | 2339 |
|
|
2020
Q4 | $102K | Buy |
+6,444
| New | +$97.2K | ﹤0.01% | 2223 |
|
|
2019
Q3 | – | Sell |
-6,893
| Closed | -$53.1K | – | 2417 |
|
|
2019
Q2 | $53.1K | Hold |
6,893
| – | – | ﹤0.01% | 2414 |
|
|
2019
Q1 | $137K | Buy |
+6,893
| New | +$120K | ﹤0.01% | 2185 |
|
|
2018
Q4 | – | Sell |
-6,360
| Closed | -$234K | – | 2606 |
|
|
2018
Q3 | $234K | Hold |
6,360
| – | – | ﹤0.01% | 2005 |
|
|
2018
Q2 | $223K | Buy |
6,360
+2,631
| +71% | +$101K | ﹤0.01% | 1880 |
|
|
2018
Q1 | $173K | Hold |
3,729
| – | – | ﹤0.01% | 1961 |
|
|
2017
Q4 | $140K | Buy |
+3,729
| New | +$163K | ﹤0.01% | 2108 |
|
MetLife Investment Management's KDNY Position: Q3 2023 in Review
MetLife Investment Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 30,585 shares — an estimated $1.18M sold.
MetLife Investment Management first reported a position in KDNY in Q4 2017 and held it in 16 quarters. The position peaked at $1.18M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- MetLife Investment Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- MetLife Investment Management sold 30,585 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.18M.
- MetLife Investment Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2017 and held it in 16 quarters.
- MetLife Investment Management's Chinook Therapeutics, Inc. Common Stock position peaked at $1.18M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on MetLife Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.